CN107382882B - 一种氯法齐明的精制方法 - Google Patents
一种氯法齐明的精制方法 Download PDFInfo
- Publication number
- CN107382882B CN107382882B CN201710619387.2A CN201710619387A CN107382882B CN 107382882 B CN107382882 B CN 107382882B CN 201710619387 A CN201710619387 A CN 201710619387A CN 107382882 B CN107382882 B CN 107382882B
- Authority
- CN
- China
- Prior art keywords
- clofazimine
- temperature
- dichloromethane
- crude
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004287 clofazimine Drugs 0.000 title claims abstract description 46
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000007670 refining Methods 0.000 title claims abstract description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 48
- 150000001298 alcohols Chemical class 0.000 claims abstract description 4
- 239000012046 mixed solvent Substances 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 12
- 239000012043 crude product Substances 0.000 abstract description 10
- 239000007859 condensation product Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- -1 clofazimine ketone Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 230000002558 anti-leprotic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 230000000605 effect on leprosy Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种氯法齐明粗品在二氯甲烷和醇类的混合溶剂中精制的方法,可有效地降低氯法齐明缩合物异构体等杂质,纯度高,并且操作简单、生产成本低,非常适合工业大生产。
Description
技术领域
本发明涉及一种氯法齐明纯化精制方法。
背景技术
氯法齐明具有良好的抗麻风活性,临床试验中显示对于瘤型麻风和其他型麻风均有一定疗效,对耐氨苯砜麻风杆菌感染也有效。其次氯法齐明具有良好的体内外抗结核分歧杆菌(MTB)活性,并且与其他抗结核药相比不易产生耐药性,还可防止结核分歧杆菌(MTB)对异烟肼发生耐药。另外氯法齐明还可以治疗艾滋病患者的对抗分歧杆菌复合群感染。
氯法齐明结构式如式I所示:
Journal of the Chemical Society,1958,p.859-863报道氯法齐明缩合物与异丙胺缩合得到氯法齐明,合成路线如下:
通过该路线合成得到的氯法齐明粗品中含有较大的氯法齐明缩合物异构体(II)、氯法齐明掉氯杂质(III)、氯法齐明酮杂质(IV)等杂质。杂质具体结构式如下:
已知的对氯法齐明粗品进行精制的方法主要通过柱层析分离,该方法局限于小试,不适用于大生产。
发明内容
本发明的目的是提从一种有效的适合工业化生产的精制氯法齐明粗品的方法。
本发明提供一种氯法齐明的精制方法,包括以下步骤:将氯法齐明粗品在二氯甲烷和醇类混合溶剂加热溶解,控温搅拌,降温析晶,过滤得到氯法齐明精制品。
作为优选的方案:
所述的醇类溶剂选自:甲醇、乙醇、正丁醇。
二氯甲烷和醇体积比例为1:1~3:1,优选为2:1。
加入二氯甲烷和醇的总量相对于氯法齐明粗品重量为4.0~8.0mL/g,优选为5.0~6.0ml/g。
控温搅拌温度为30~50℃,优选为38~43℃。其中控温搅拌时间为1~3小时,,优选为2小时。
其中降温析晶过程中冷却温度至0~5℃,优选2~5℃。
本发明有意义的技术效果是通过在二氯甲烷和醇类溶剂对氯法齐明粗品进行精制,有效地降低氯法齐明缩合物异构体等杂质,纯度能高达99%(HPLC)以上,并且操作简单、生产成本低,非常适合工业大生产。
具体实施方式
实施例1:氯法齐明粗品的精制
取氯法齐明粗品(其中含氯法齐明缩合物异构体(II)含量为10.0%,氯法齐明掉氯杂质(III)1.2%,氯法齐明酮杂质(IV)含量为1.0%,)200g,液相色谱显示粗品中氯法齐明的含量为85.0%,加入二氯甲烷660mL、甲醇330mL,加热溶解,控温40℃搅拌2小时,搅拌降温至2℃,抽滤、烘干得固体棕红色产物155g,氯法齐明纯度(HPLC)99.7%。
实施例2:氯法齐明粗品的精制
取氯法齐明粗品(氯法齐明缩合物异构体(II)含量为10.0%,氯法齐明掉氯杂质(III)1.2%,氯法齐明酮杂质(IV)含量为1.0%,)200g,液相色谱显示粗品中氯法齐明的含量为85.0%,加入二氯甲烷660mL、乙醇330mL,加热溶解,控温40℃搅拌2小时,搅拌降温至2℃,抽滤、烘干得固体棕红色产物148g,氯法齐明纯度(HPLC)99.3%。
实施例3:氯法齐明粗品的精制
取氯法齐明粗品(氯法齐明缩合物异构体(II)含量为10.0%,氯法齐明掉氯杂质(III)1.2%,氯法齐明酮杂质(IV)含量为1.0%,)200g,液相色谱显示粗品中氯法齐明的含量为85.0%,加入二氯甲烷400mL、甲醇400mL,加热溶解,控温30℃搅拌1小时,搅拌降温至0℃,抽滤、烘干得固体棕红色产物140g,氯法齐明纯度(HPLC)99.4%。
实施例4:氯法齐明粗品的精制
取氯法齐明粗品200g,液相色谱显示粗品中氯法齐明的含量为85.0%,加入二氯甲烷1200mL、甲醇400mL,加热溶解,控温50℃搅拌3小时,搅拌降温至5℃,抽滤、烘干得固体棕红色产物135g,氯法齐明纯度(HPLC)99.5%。
实施例5:氯法齐明粗品的精制
取氯法齐明粗品200g,液相色谱显示粗品中氯法齐明的含量为85.0%,加入二氯甲烷660mL、正丁醇330mL,加热溶解,控温40℃搅拌2小时,搅拌降温至2℃,抽滤、烘干得固体棕红色产物138g,氯法齐明纯度(HPLC)99.3%。
下表1是粗品和实施例1-5精制前后的HPLC检测实验结果对比:
表1
Claims (10)
1.一种氯法齐明的精制方法,其特征在:将氯法齐明粗品在二氯甲烷和醇类混合溶剂进行重结晶;所述的醇类溶剂选自:甲醇、乙醇、正丁醇;其中二氯甲烷和醇体积比例为1:1~3:1。
2.根据权利要求1所述的方法,所述重结晶包括以下步骤:将氯法齐明粗品在二氯甲烷和醇类混合溶剂加热溶解,控温搅拌,降温析晶,过滤得到氯法齐明精制品。
3.根据权利要求1所述的方法,其中二氯甲烷和醇体积比例为2:1。
4.根据权利要求1所述的方法,其中加入二氯甲烷和醇的总量相对于氯法齐明粗品重量为4.0~8.0mL/g。
5.根据权利要求4所述的方法,其中加入二氯甲烷和醇的总量相对于氯法齐明粗品重量为5.0~6.0ml/g。
6.根据权利要求1所述的方法,其中控温搅拌温度为30~50℃。
7.根据权利要求6所述的方法,其中控温搅拌温度为38~43℃。
8.根据权利要求1所述的方法,其中控温搅拌时间为1~3小时。
9.根据权利要求1所述的方法,其中降温析晶过程中冷却温度至0~5℃。
10.根据权利要求9所述的方法,其中降温析晶过程中冷却温度至2~5℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710619387.2A CN107382882B (zh) | 2017-07-26 | 2017-07-26 | 一种氯法齐明的精制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710619387.2A CN107382882B (zh) | 2017-07-26 | 2017-07-26 | 一种氯法齐明的精制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107382882A CN107382882A (zh) | 2017-11-24 |
CN107382882B true CN107382882B (zh) | 2022-03-25 |
Family
ID=60341732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710619387.2A Active CN107382882B (zh) | 2017-07-26 | 2017-07-26 | 一种氯法齐明的精制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107382882B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108892647A (zh) * | 2018-08-06 | 2018-11-27 | 浙江华海立诚药业有限公司 | 一种氯法齐明晶型的结晶方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592814A (en) * | 1967-10-26 | 1971-07-13 | May & Baker Ltd | Phenazine derivatives |
EP0676201A2 (en) * | 1994-04-05 | 1995-10-11 | Adcock Ingram Limited | Use of a riminophenazine for treating MDR resistance |
CN106749230A (zh) * | 2016-12-20 | 2017-05-31 | 东北制药集团股份有限公司 | 一种长春胺的制备方法 |
-
2017
- 2017-07-26 CN CN201710619387.2A patent/CN107382882B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592814A (en) * | 1967-10-26 | 1971-07-13 | May & Baker Ltd | Phenazine derivatives |
EP0676201A2 (en) * | 1994-04-05 | 1995-10-11 | Adcock Ingram Limited | Use of a riminophenazine for treating MDR resistance |
CN106749230A (zh) * | 2016-12-20 | 2017-05-31 | 东北制药集团股份有限公司 | 一种长春胺的制备方法 |
Non-Patent Citations (1)
Title |
---|
Clofazimine;Caitriona M .et al.;《Analytical Profiles of Drug Substances and Excipients》;19921231;第21卷;第75-108页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107382882A (zh) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02500738A (ja) | 抗腫瘍組成物およびその使用法 | |
CN108948020B (zh) | 一种枸橼酸托法替布的精制方法 | |
CN107382882B (zh) | 一种氯法齐明的精制方法 | |
CN110294683A (zh) | 一种甜菜碱酚酸离子盐及其制备方法与应用技术领域 | |
CN112500309B (zh) | 一种对乙酰氨基酚粗品的纯化方法 | |
CN103319548B (zh) | 一种蔗糖-6-乙酸酯的提纯方法 | |
US1867274A (en) | Resolution of ephedrine and its homologues and of mandelic acid, and certain intermediates | |
WO2019171222A9 (en) | Crystalline forms of venetoclax | |
CN104098547B (zh) | 一种盐酸法舒地尔的精制方法 | |
US3401194A (en) | Process for the resolution of stereoisomers from racemic 1-hydroxy-2-amino butane | |
CN106167465B (zh) | 一种依达拉奉二聚体杂质化合物及其制备方法 | |
EP3383885B1 (en) | Crystallization of 25-hydroxy-7-dehydrocholsterol | |
CN115536558B (zh) | 一种布美他尼粗品的精制工艺 | |
CN105753902B (zh) | 一种福司氟康唑的制备方法 | |
EP2160376A2 (en) | Novel crystalline forms of atovaquone | |
CN107459503B (zh) | 一种甘草素的分离纯化方法 | |
CN108822063A (zh) | 一种丁二酸酐的分离提纯方法 | |
CN109422679B (zh) | 一种贝达喹啉的纯化及稳定晶型的制备方法 | |
JP2013184929A (ja) | コレステロールの精製方法 | |
CN109180759B (zh) | 一种从甘草废渣中分离纯化芒柄花苷的方法 | |
CN117229342A (zh) | 一种甘氨胆酸的纯化方法 | |
Hibbert et al. | STUDIES ON REACTIONS RELATING TO CARBOHYDRATES AND POLYSACCHARIDES. XIX. STRUCTURAL, GEOMETRICAL AND OPTICAL ISOMERISM OF THE PARA-NITROBENZYLIDENE GLYCEROLS AND THEIR DERIVATIVES | |
US2540243A (en) | Process for preparing isomers of methyl pentaacetyldihydrostreptobiosaminide | |
KR100650318B1 (ko) | 용해도 차이를 이용한 진세노사이드 이성질체 분리 방법 | |
JP2017007965A (ja) | ピルビン酸ナトリウムの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |